Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio
Aiming To Challenge Pfizer In Cardiomyopathy
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.